NCT01244646终止不适用
Perceived Hypoglycemia- and Weight-related Quality of Life of Patients With Sulfonylurea Derivate-treated Diabetes Mellitus Type 2, a Non-interventional Study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- AstraZeneca
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire
研究概览
简要总结
- A prospective, non-interventional study, 125 patients with Diabetes Mellitus Type2 will be enrolled, who, while on metformin, have a sub-optimal glycemic control and who thus will receive additional treatment with a sulfonylurea (SU) derivative. At the start and at 3 and 6 months, during regular visits to the patient's General Practitioner, the patients will complete a series of questionnaires (Patient Reported Outcomes, PROs) directed at diabetes in general, at fear for hypoglycemia, at body weight, at treatment compliance and at general wellbeing. These PROs are the worry subscale of the Hypoglycaemic Fear Survey, Impact of Weight on Quality of Life, revised Diabetes Symptom Checklist, Problem Areas In Diabetes, EuroQol EQ-5D and Medication Adherence Report Scale. In total 75 questions. The frequency of hypoglycemic symptoms, incidence of hypoglycemic events and body weight changes will be assessed and the level of adherence to treatment will be investigated.
- Diabetic patients, M/F, aged >35, metformin treated, serum HbA1c ≥7.0% (within last month), informed consent provided, in whom a SU therapy is added. Patients with Type 1 diabetes and with secondary diabetes will be excluded, and patients unable to understand and complete the questionnaires.
- Primary outcome variables are outcomes from HFS-w and IWQOL in relation to the frequency of hypoglycemic symptoms and body weight at 6 months and to weight change from 0 to 6 months. Secondary outcome variables are the other PROs. The frequency of hypoglycemic symptoms, incidence of hypoglycemic events, changes in body weight and level of compliance will be addressed.
- The Intention To Treat analysis will be used, with Last Value Extended Forward from 3 to 6 months in case of withdrawal after 3 months. Changes in outcome variables will be analysed by modelling time and potential dummy variables in a Generalized Estimating Equations analysis.
- Secondary, outcomes in HFS-w and IWQOL are compared with self-reported hypoglycemic symptoms, incidence of hypoglycemic events, body weight and change in body weight from 0 to 6 months. Changes in all PRO's from 0 to 3 and 6 months, potential relationships between (changes in) the different questionnaires, such as with hypoglycemia symptoms, weight (changes) and treatment compliance will be evaluated. A search is done for baseline characteristics which predict outcomes and changes in PRO's, hypoglycemic symptoms, hypoglycemic events and weight changes.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 35 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diabetes Mellitus Type 2 for > 6 months on treatment with only metformin for >4 weeks
- •HbA1c value >7.0 and therefore a sulfonylurea derivative is added
- •Able to complete a series of questionnaires
排除标准
- •Concomitant treatment with an other antidiabetic than metformin and SU derivative
- •Contraindications for the use of metformin or SU derivative
- •Concomitant diseases which may affect the patient's ability to complete study
结局指标
主要结局
Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire
时间窗: 6 months
Hypoglycemic Fear Survey (HFS) questionnaire
时间窗: 6 months
次要结局
- Diabetes Symptom Checklist (DSC-R) questionnaire,(6 months)
- Medication Adherence Report Scale (MARS-5) questionnaire(6 months)
- Investigator-asked Symptoms of Hypoglycemia, hypoglycemic events, weight, compliance(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Risk of Hypoglycemia in Type 2 DiabetesType 2 DiabetesNCT00734669University of Giessen12
尚未招募
不适用
Hypoglyemia in Type 2 Diabetes Mellitus Patients Taking Oral Antidiabetic MedicationsCTRI/2022/06/043496Maulana Azad Medical College
尚未招募
Unknown
A Study on Quality of Life in Type 2 Diabetes mellitus PatientsCTRI/2023/11/059912Government siddha medical College, Chennai
已完成
不适用
O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and KuwaitDiabetes Mellitus, Type 2NCT05716724Novo Nordisk A/S288
已完成
3 期
Double blind, randomised, comparative, multicentre, parallel-group study design to evaluate the effects of Pioglitazone on cardiovascular risk markers in type 2 diabetes mellitusACTRN12608000534381Takeda Italia Farmaceutici S.p.A.100